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ABSTRACT
Androgen receptor (AR) is a ligand-controlled
transcription factor frequently deregulated in pros-
tate carcinomas. Since there is scarce information
on the action of AR on the chromatin level, we have
elucidated the molecular mechanisms underlying
the androgen-dependent regulation of immunophilin
FKBP51 in prostate cancer cells. In comparison
to the canonical AR target PSA, FKBP51 is more
rapidly and strongly induced by androgen, with the
regulation occurring merely at the transcriptional
level. FKBP51 locus harbors 13 in silico-predicted
androgen response elements (AREs), with most
of them located downstream from transcription
start site (TSS) and capable of binding AR in vitro.
Chromatin immunoprecipitation assays in VCaP
and LNCaP prostate cancer cells indicate that
activation of the locus by the AR relies on four
major intronic sites, with the compound ARE-con-
taining sites  90kb downstream from the TSS play-
ing critical roles. Binding of agonist-loaded AR onto
these sites in vivo was accompanied with significant
recruitment of RNA polymerase II and BRM-contain-
ing chromatin remodeling complexes to the FKBP51
locus, which resulted in changes in the histone
density of the locus. Our results indicate that very
distal AREs act as genuine and robust enhancers,
highlighting the importance of long-range regulation
of transcription by the AR.
INTRODUCTION
Androgen receptor (AR) is a hormone-inducible tran-
scription factor that belongs to the nuclear receptor super-
family (1). Many of the genes regulated by androgens
and AR program the development and maintenance of
the male phenotype and sexual characteristics. AR also
plays a critical role in controlling the malignant growth
of prostate tumors, and androgen ablation is a standard
therapy for prostate cancer. However, the therapy usually
eventually fails and cancer turns into a lethal hormone-
refractory state that overexpresses AR and is thereby sen-
sitized to low androgen levels (2,3).
Transcription is regulated at many levels. DNA
sequence forms platforms for binding of transcription
factors that can either activate or attenuate transcription
of a given gene. Androgen receptor’s binding sites in
DNA, androgen response elements (AREs), are essential
for AR-mediated transcriptional activation, but not
necessary for transcriptional repression by the receptor
(4,5). However, not all AREs that are capable of binding
AR in vitro necessarily function in vivo, since epigenetic
regulation of chromatin structure and packaging can
prevent their accessibility. Major epigenetic mechanisms
that regulate chromatin structure include modiﬁcations
of nucleosomes and DNA methylation (6,7).
Activation of genes by the AR requires, in addition to
basal transcription machinery and RNA polymerase II,
transcriptional coregulator proteins. Many coregulatory
proteins harbor or recruit enzymatic activities that
covalently modify histones (8). Agonist-bound nuclear
receptors can interact with coactivator proteins linked to
histone acetyltransferase activity, which acetylates speciﬁc
lysine (K) residues in nucleosomal histones. Also histone
methylation has recently been implicated in nuclear recep-
tor signaling (9). In contrast to histone acetylation that is
connected to active transcription, methylation of histones
by K- or arginine (R)-speciﬁc activities have been linked to
both activation and repression of transcription. The eﬀect
of these histone methylations on gene activity depends on
the identity of the amino acid residue in a speciﬁc histone
modiﬁed. For example, methylation of histone H3 at K9
and K27 are repressive modiﬁcations (transcriptional
‘oﬀ’ state), whereas methylation of H3 at K4 and K36
are needed for active transcription (transcriptional ‘on’
state) (6,10).
Nuclear receptors also attract chromatin remodeling
complexes which utilize the energy of ATP to alter the
histone-DNA association. Consequences of remodeling
by SWI/SNF complexes include nucleosome sliding,
alterations in nucleosome structure and histone octamer
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of transcription factor binding sites. SWI/SNF complexes
contain either BRM (SMARCA2) or BRG1 (SMARCA4)
as a central ATPase subunit (14). It is not totally clear
whether these ATPases are fully replaceable with each
other or if there is some tissue or gene speciﬁcity in their
function (15).
Perturbations in the transcriptional programs of AR are
important, but poorly understood, events in prostate
cancer. Knowledge of the AR action under genuine chro-
matin milieu is therefore essential for better understanding
of the molecular mechanisms underlying prostate cancer
development. However, regulation of only few AR target
loci has thus far been characterized in a detailed fashion
at the chromatin level. Most studies have been focusing
on the prostate speciﬁc antigen (PSA) (16–20) of which
protein product’s serum concentration is used in prostate
cancer diagnostics (21). Even though PSA has been
studied as an example of ‘canonical’ AR target gene
in prostate cells, it does not appear to be very sensitive
to androgen levels in vivo, as PSA mRNA levels were
not signiﬁcantly suppressed in prostatectomy patients in
response to androgen deprivation therapy (22). Compared
to PSA mRNA, for example FKBP51 (FKBP5) mRNA
much better reﬂects the androgen concentration and
activity in human prostate (22).
In the present study, we have focused on the androgen
regulation of FKBP51 in VCaP cells derived from a hor-
mone-refractory prostate cancer (23). Our results show
that in comparison to PSA, FKBP51 mRNA is more
robustly induced by androgens, with the regulation occur-
ring merely at the level of transcription, as it is cyclo-
heximide-independent but actinomycin D sensitive.
Quantitative chromatin immunoprecipitation scans and
enhancer activity analyses indicate that the androgen acti-
vation of the FKBP51 locus occurs via several distal intro-
nic enhancers, with the compound AREs located at  90
and  100kb from the transcription start site playing the
major role. Binding of AR to these distal enhancers is
accompanied with chromatin remodeling throughout the
locus. In LNCaP cells, that contain less AR than VCaP
cells, AR occupancy and induction of the locus in
response to androgen were less robust than in VCaP
cells, but the pattern of the receptor loading was similar
and the same intronic enhancers were important in both
prostate cancer cell types. A model for long-range regula-
tion by AR transcription complexes on the FKBP51 locus
in vivo is presented.
MATERIALS AND METHODS
Cell culture
VCaP and LNCaP cells were from American Type Culture
Collection (ATCC). VCaP cells were maintained in
DMEM containing 10% US deﬁned FBS (HyClone,
Logan, Utah, USA), 25U/ml penicillin and 25mg/ml
streptomycin in a 5% CO2 atmosphere at 378C. LNCaP
cells were grown in RPMI 1640 supplemented according
to instructions from ATTC and FBS as above. COS-1 cells
were maintained in DMEM containing 10% FBS, penicil-
lin (6.25U/ml) and streptomycin (6.25mg/ml).
DNA constructs
Selected regions of FKBP51 were PCR cloned from
human genomic DNA using Phusion DNA polymerase
(Finnzymes, Espoo, Finland) and subcloned into the
TATA box-containing pGL3-basic (Promega, Madison,
WI, USA). Primers used were the same as listed
for ChIP except for region 12 the forward primer was
50-TCTTGCCTCCAACACTGCTG-30 (Supplementary
Table S1). All sequences were veriﬁed by DNA sequencing
using the ALFexpress system. pCMV encoding b-galacto-
sidase was from Clontech (Mountain View, CA, USA).
Antibodies
Primary antibodies purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA): AR (sc-816),
BRG1 (sc-10768), TRAP220 (sc-8998), FKBP51
(sc-13983), GADPH (sc-25778), and normal rabbit IgG
(sc-2027); from Abcam (Cambridge, UK): H3 (ab1791),
H3K4me3 (ab8580) and H3K36me3 (ab9050); from
Covance (Emeryville, CA, USA): PolII (MMS-126R);
from UpState (Lake Placid, NY, USA): H3K9,K14ac
(06-599); and from BD Biosciences (San Jose, CA,
USA): BRM (610389).
Isolation of RNA and quantitative real-time RT–PCR
(qRT-PCR)
VCaP and LNCaP cells were seeded onto 6-well plates
(8 10
5 and 3.3 10
5cells/well, respectively) and grown
36h in transfection medium [DMEM containing 2.5%
charcoal-stripped FBS (CCS-FBS)] devoid of steroids.
Subsequently, cells were treated with or without synthetic
androgen agonist R1881 (Perkin Elmer Inc., Waltham,
MA, USA), 5a-dihydrotestosterone (Steraloids Inc.,
Newport, RI, USA) or bicalutamide (Zeneca
Pharmaceuticals, Macclesﬁeld, UK) as indicated. Total
RNA was extracted using TRIzol Reagent (Invitrogen
Lifetechnologies, Carlsbad, CA, USA) and converted to
cDNA using Transcriptor First Strand cDNA synthesis
Kit (Roche Diagnostics GmbH, Mannheim, Germany)
following manufacturer’s instructions. cDNA was used
as a template in qRT-PCR, which was carried out using
MX3000P real-Time PCR System (Stratagene, La Jolla,
CA, USA), FastStart SYBR Green Master (Roche)
and speciﬁc primers for FKBP51, PSA, TMPRSS2 and
GAPDH (Supplementary Table S1). Analyzed GAPDH
mRNA levels were used to normalize the amounts
of total RNA between the samples. Fold changes were
calculated using the formula 2
 (Ct), where Ct is
Ct(R1881)–Ct(EtOH), Ct is Ct(gene X)–Ct(GAPDH) and
Ct is the cycle at which the threshold is crossed.
Electrophoretic mobility shift assay (EMSA)
For production of AR for EMSAs, COS-1 cells were
transfected either with empty pSG5 or pSG5-hAR
and cell extracts were prepared as described (24).
Twelve micrograms of cell extract was used for 20ml
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ethanol and AR extract with 10nM R1881.
32P-labeled
ds-oligomer probe was added and protein–DNA com-
plexes were allowed to form for 1h (25). The intronic
ARE 50-AGTACGtgaTGTTCT-30 (core) of rat prostatein
peptide C3(1) was used as a positive control. Probes con-
tained the 27bp native sequences (Supplementary
Table S1). The complexes were separated on 4% non-
denaturing PAGE. The gels were dried and detected
using phosphoimager (FLA3000, Fuji, Japan).
Reporter gene assay (RGA)
VCaP and LNCaP cells were seeded onto 12-well plates
(3.2 10
5 and 1.4 10
5cells/well, respectively) and grown
4h in transfection medium. The cells were transfected
with reporter gene constructs (1.8mg pLUC and 0.2mg
pCMVb/well) using jetPEI
TM (Polyplus-transfection
SA, Illkirch, France) transfection reagent. COS-1 cells
were seeded onto 12-well plates (1.4 10
5cells/well)
and grown 4h in transfection medium. The cells were
transfected with reporter gene constructs (0.46mg pLUC,
0.02mg pCMVb/well and 0.02mg pSG5-hAR) using
TransIT–LT1 (Mirus Bio Corporation, Madison, WI,
USA) transfection reagent. One day after transfection,
the cells were grown for 16h with either vehicle (ethanol)
or 1nM R1881 and lysed in Reporter Lysis Buﬀer
(Promega, Madison, WI, USA) and LUC activity
was measured with Luciferase Assay System (Promega)
using Luminoskan Ascent (Thermo Electron, Helsinki,
Finland) luminometer and b-galactosidase activity as
described (25).
Chromatin immunoprecipitation assay (ChIP)
VCaP and LNCaP cells were seeded at  70% conﬂuence
onto 75cm
2 bottles and allowed to grow in steroid-
depleted transfection medium for 48h prior to ChIP.
The experiments were performed essentially as previously
described (26), except for short-term assays ( 2h), the
cells were treated with 2.5mM a-amanitin (Sigma-
Aldrich, St Louis, MO, USA) for 2h to further synchro-
nize the cell population (27) prior to addition of androgen.
a-Amanitin was removed by washing twice with PBS,
and R1881 was added to the medium for indicated
times. Speciﬁc primers for diﬀerent regions are listed in
Supplementary Table S1. Quantitative PCR analyses
were carried out with FastStart SYBR Green Master
and MX3000P Real-Time PCR System. Results were cal-
culated using the formula E
 (Ct) 10, where E (eﬃciency
of target ampliﬁcation) is a coeﬃcient of DNA ampliﬁca-
tion by one PCR cycle for a particular primer pair and
Ct is Ct(ChIP-template)–Ct(Input). In Figures 5 and 6, results
were presented as fold over the value of normal rabbit
IgG-precipitated samples.
Immunoblotting
Cell monolayers were washed with ice-cold TBS
and harvested in TBS. Cell pellets were suspended in
SDS-PAGE sample buﬀer and lysed by sonication and
lysed by sonication 2 10s. Samples were heated for
5min at 958C and separated on 7.5% SDS-PAGE gels.
Proteins were transferred onto nitrocellulose membranes
and visualized by indicated antibody and horseradish per-
oxidase-conjugated anti-rabbit antibody using the
enhanced chemiluminescence detection reagents according
to the manufacturer’s instructions (Pierce). For protein
quantiﬁcation, the proteins were visualized by goat anti-
rabbit IgG DyLight
TM 680 conjugated secondary anti-
body. Quantiﬁcation of the immunoblots was performed
by scanning with Li-COR Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE, USA) at
700nm channel according to manufacturer’s instructions.
AR and FKBP51 protein amounts were normalized with
GADPH amounts (assessed with a speciﬁc antibody) in
each sample.
RESULTS
Rapid and robust induction of FKBP51 transcription
by androgen
To study the androgen regulation of FKBP51 of human
prostate VCaP cancer cells, we isolated RNA at diﬀerent
periods after addition of androgen (R1881; 0, 1.5, 3, 6, 12
and 18h) and performed qRT-PCR analysis. As shown in
Figure 1A, FKBP51 mRNA is rapidly and strongly
induced after androgen exposure, with the induction
being >20-fold at 3h and peaking ( 60-fold) at 12h.
Compared to the FKBP51, the induction of PSA was
much slower and less impressive. Another AR target
gene TMPRSS2 showed similar induction kinetics as
FKBP51, but its overall induction remained modest
( 10-fold) in comparison to FKBP51. Since the FKBP51
mRNA persisted at a high level after 12h, we checked
whether that was mainly due to new mRNA synthesis or
by mRNA stabilization. To that end, we terminated
mRNA synthesis by adding actinomycin D to the cells
at 12h after the androgen exposure and monitored the
amount of FKBP51 mRNA at further time points.
Decline of the FKBP51 mRNA level after addition of
actinomycin D indicates that the AR-mediated transcrip-
tional response continues for prolonged times, at least
until 36h after androgen exposure (Figure 1B, data not
shown). To conﬁrm that the gene is a direct transcrip-
tional target for AR, the cells were treated with or without
translation inhibitor cycloheximide (CHX) and qRT-PCR
analyses were performed. CHX did not inhibit the andro-
gen induction of FKBP51 (but actually enhanced it;
p<0.001) or TMPRSS2 mRNA (p>0.05), whereas it
nearly abolished the androgen induction of PSA mRNA
(p<0.05) (Figure 1C). These results indicate that, in con-
trast to PSA, the androgen regulation of FKBP51 and that
of TMPRSS2 does not require de novo protein synthesis.
The eﬀect of CHX on the PSA mRNA is in line with
previous ﬁndings in other prostate cancer cell types
(26,28).
We next tested whether the androgen activation of
FKBP51 in VCaP cells diﬀers from that in LNCaP cells
which are often used as a model of prostate cancer cells.
We ﬁrst compared the AR protein levels in the two cell
lines by immunoblotting with anti-AR antibody. In keep-
ing with the ampliﬁcation of AR in VCaP cells (23),
Nucleic Acids Research, 2009,Vol.37, No. 12 4137but not in LNCaP cells, quantiﬁcation of the AR bands
showed that VCaP cells contain  3–7-fold more AR pro-
tein than LNCaP cells, with the diﬀerence being depen-
dent on the presence of androgen in the culture medium
(Figure 1D). Interestingly, androgen exposure had a recip-
rocal eﬀect on AR levels in the two cell lines; it repeatedly
decreased the amount of the receptor in VCaP cells and
increased it in LNCaP cells.
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Figure 1. Rapid and robust augmentation of FKBP51 transcription in response to androgen exposure in prostate cancer cells. (A) Accumulation
of FKBP51, TMPRSS2 and PSA mRNA in response to androgen treatment in VCaP cells. Cells were treated with 1nM synthetic androgen R1881
for indicated times and mRNAs were analyzed by qRT-PCR analysis. (B) To test whether the FKBP51 mRNA accumulation after 12h androgen
treatment was caused by new mRNA synthesis or mRNA stabilization, cells were further grown in the presence or absence of actinomycin D
(1mg/ml) for indicated times and qRT-PCR was performed. (C) VCaP cells were treated with vehicle (ethanol, EtOH) or R1881 for 24h in the
presence and absence of translation inhibitor cycloheximide (CHX, 10 mg/ml) and qRT-PCR analyses were performed. Total RNA levels between
samples were normalized using mRNA levels of GAPDH. Fold changes were calculated as described in Materials and Methods. Columns represent
the mean SD of three independent experiments. (D) Immunoblotting analysis of AR protein levels in VCaP and LNCaP cells grown for 18h with
vehicle (EtOH) or androgen (1 or 10nM 5a-dihydrotestosterone, DHT) as indicated. AR was detected using anti-AR antibody as described in
Materials and Methods. (E) Time course of AR target gene mRNA accumulation in LNCaP cells was carried out as in panel A. (F) Immunoblotting
analysis of FKBP51 protein levels in VCaP and LNCaP cells cultured in the presence and absence of androgen as in panel D.
4138 Nucleic Acids Research, 2009, Vol. 37,No. 12In comparison to VCaP cells, the fold-induction of
FKBP51 mRNA by androgen was weaker and it peaked
later in LNCaP cells (Figure 1E). Silencing of AR expres-
sion in VCaP cells was paralleled by a marked reduction in
the androgen-induced accumulation of FKBP51 mRNA
(Supplementary Figure S1), supporting the notion that the
weaker induction of FKBP51 in LNCaP cells is mainly due
to the lower amount of AR in those cells. Moreover, the
curve of FKBP51 mRNA accumulation in response to
increasing androgen concentrations was shifted to the
right compared to the situation in VCaP cells
(Supplementary Figure S2). In both prostate cancer cell
lines, induction of FKBP51 by androgen was also mani-
fested on the FKBP51 protein level (Figure 1F).
FKBP51 locus harbors several potential AR-binding sites
The above data strongly suggest that FKBP51 is directly
targeted by AR and mainly at the transcriptional level.
Moreover, the robust androgen induction of FKBP51
implies that there may be more than one ARE-containing
region within the gene. To identify potential AREs in the
FKBP51, we performed in silico analysis from –20kb
upstream of its TSS to 20kb downstream from its last
exon (exon 11) spanning  155kb in chromosome 6
using the CONSITE program (http://asp.ii.uib.no:8090/
cgi-bin/CONSITE/consite/). The score cutoﬀ was adjusted
to 80% and the position weight matrix provided by the
program was used. After program-based screening, puta-
tive AREs were further manually sifted using G at posi-
tion 2 and C at position 5 in the half-site as the criterion
(Figure 2B). This process resulted in identiﬁcation of
13 putative AREs (AREI–AREXIII, Figure 2B) of
which all, excluding AREI, were located within the introns
of FKBP51 (Figure 2A). Only two of the AREs, AREIII
and AREXI, show characteristics of selective AREs con-
sisting of two hexameric half-sites arranged as a so-called
androgen direct repeat separated by a 3-nt spacer (DR3),
whereas the other 11 elements resemble 3-nt-spaced
inverted repeats of (IR3) of a 50-TGTTCT-30-like half-
site (29). Interestingly, AREVIII and AREIX in the ﬁfth
intron (at  87kb from the TSS) are separated from each
other only by 16nt. Similarly, AREX, AREXI and
AREXII are clustered within 215nt in the 7th intron
(at  98kb from the TSS).
To test the capability of the putative 13 AREs to bind
AR in vitro, we performed electrophoretic mobility shift
assays with recombinant human AR from COS-1 cells.
AR was incubated with dsDNA oligomers containing
the 15bp core element of a given putative ARE sur-
rounded by 6bp native ﬂanking sequences. The intronic
ARE of the rat prostatein peptide C3(1) that binds
eﬃciently AR in vitro was used as a positive control
(30). In EMSAs, nine AREs, AREIII–VI, AREVIII–XI,
and AREXIII, showed AR–DNA complex formation that
was >25% of that of the positive control ARE (Figure 2C
and Supplementary Figure S3). EMSAs with mutated oli-
gomers containing A instead of G or C in the 2nd and 5th
position of one half-site of AREIX (IXm) and AREXIII
(XIIIm) conﬁrmed the speciﬁcity of AR–ARE interaction
and the importance of both half-sites for the interaction
(Figure 3C, on the right). The high portion of the pre-
dicted AREs capable of eﬃciently interacting with the
receptor indicates the biochemical relevance of our in
silico screen.
Function of the FKBP51 AREs as enhancers
The above EMSA results suggest that there are several
potential AREs within the FKBP51 locus. We next
tested their function as androgen-regulated enhancers in
prostate cancer cells. Approximately 300-nt regions cover-
ing the AREs (cf. Figure 2A) were cloned in front of a
TATA-box containing luciferase plasmid. VCaP cells were
transfected with the plasmids and treated with or without
androgen. Empty TATA-box containing luciferase plas-
mid served as a negative control. As shown in
Figure 2D, region 11 harboring the AREVIII and
AREIX and region 12 harboring the AREX, AREXI
and AREXII were the only regions conferring signiﬁcant
androgen induction in VCaP cells, with the region 12
showing the strongest activity and androgen induction
( 10-fold). These two FKBP51 regions displayed strong
androgen induction also in COS-1 cells cotransfected
with an AR expression vector. In addition, region 7 that
showed only a modest induction (1.7-fold) in VCaP cells
conferred in COS-1 cells a strong androgen induction
(Figure 2E). Androgen induction of the regions 11 and
12 was weaker in LNCaP than in VCaP cells (cf.
Figure 2D and F). Ectopic expression of AR to some
extent strengthened the induction through the region 12
in LNCaP cells (Figure 2G), suggesting that the diﬀerence
in the eﬀect of androgen between the two prostate cell
lines reﬂects the amount of AR in these cell lines.
However, the region 12 harboring three AREs conferred
the strongest androgen induction in all studied cell types.
Taken together, these results suggest that there are two
major distally located enhancers ( 87kb from the TTS)
that function in the androgen regulation of the FKBP51 in
prostate cancer cells.
Loading of AR onto FKBP51 chromatin in response to
androgen
We next analyzed the interaction of AR with the FKBP51
locus in vivo by performing chromatin immunoprecipita-
tions (ChIP) in VCaP cells with anti-AR antibody
followed by real-time PCR analysis. Altogether 14 regions
of FKBP51 were scanned. In addition to the regions har-
boring the in silico-predicted AREs, these assays included
four regions without predicted AREs, two on both sides
of the TSS (regions 2 and 3), one within ﬁrst intron
(region 8) and one downstream (region 14) the gene
(Figure 2A). PSA upstream ( 4kb) enhancer and promo-
ter, and TMPRSS2 upstream ( 13.5kb) enhancer regions
served as positive controls (20,26), and a region located in
the middle of non-androgen responsive DSCAM gene (in
chromosome 22) served as a negative control. VCaP cells
were exposed to androgen for various time points
(0–120min at 20min intervals) prior to ChIPs. Loading
of AR was clearly detectable onto several regions within
the FKBP51 locus at the 20min time point (Figure 3A).
Regions 11 and 12 were the two FKBP51 regions showing
Nucleic Acids Research, 2009,Vol.37, No. 12 4139Figure 2. Binding of AR to putative FKBP51 AREs in vitro and their function as enhancers. (A) Schematic locations of the AREs and regions
analyzed in reporter and ChIP assays. Bars depict the positions of exons and an arrow indicates the transcription start site. Roman numerals depict
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induced marked enrichment of the receptor ( 10-fold)
also onto regions 7 and 10. Binding of holo-AR peaked
at the 60min (region 11) or 80min time point (regions 7,
10 and 12). Similar kinetics of AR loading was observed
with the PSA and TMPRSS2 enhancers. Thus, AR can
in vivo interact with several separated sites that are very
distal and downstream from the FKBP51 TSS. However,
the occupancy level of holo-AR on those sites in chroma-
tin did not directly correlate with their isolated enhancer
activity in VCaP cells, in that the region 11 showed less
activity than the region 12 as an enhancer and the inter-
action of AR with regions 7 and 10 in the chromatin was
more prominent than expected on the basis of their very
weak function as isolated androgen-regulated enhancers.
Interestingly, there was also a delayed loading of holo-AR
at the 100min time point at region 3 that does not contain
any potential ARE.
Since actinomycin D experiments (Figure 1B) indicate
that the FKBP51 is still actively transcribed after 12h of
the androgen addition, we also monitored the loading of
AR onto the region 11 at later time points. ChIP assays
showed that the amount of AR bound to the FKBP51
decline after 6h, i.e. earlier than the observed peak of
the FKBP51 mRNA accumulation (cf. Figures 3B and
1A). These results suggest that after the initial peaking
of AR binding to the FKBP51 and activation of transcrip-
tion, declining amounts of AR are still suﬃcient to main-
tain the maximal androgen-activated transcription of the
locus.
Histone marks and density reflect active chromatin
structure in FKBP51 locus
Since the above ChIP assays indicate that most of the AR
binding to the FKBP51 locus occurs to sites that are very
distal to the TSS, it was of interest to monitor the occu-
pancy and recruitment of RNA polymerase II (PolII)
within the locus. In keeping with the augmenting eﬀect
of androgen on the FKBP51 transcription, addition of
androgen was accompanied with a clear increase in the
occupancy of PolII throughout the locus as assessed by
ChIP using an antibody against the largest subunit of the
PolII in VCaP cells (Figure 4B). The relative occupancy of
PolII was higher just downstream from the TSS, in the
middle of the locus, and at the 30 end of the gene than
other gene regions. Thus, PolII occupancy does not mirror
the loading of AR to the locus, suggesting that chromatin
loop formation is involved in the recruitment of PolII by
the holo-AR.
We next investigated possible changes in chromatin
structure of the FKBP51 locus upon androgen induction.
Covalent modiﬁcations of core histones reﬂect the chro-
matin activity, i.e. whether it is in ‘closed’ or ‘open’ con-
formation. For example, acetylation (ac) of histone 3 K9
and K14 and trimethylation (me3) of both H3K4 and
H3K36 are linked to active chromatin conformation
(31–34). We scanned the occurrence of the above modiﬁ-
cations by using H3 modiﬁcation speciﬁc antibodies in
ChIP analyses. As shown in Figure 4D and E, both
H3K9,14ac and H3K4me3 levels clearly peaked around
and immediately downstream the TSS, whereas
H3K36me3 marks were elevated more downstream from
the TSS and remained elevated throughout the reading
frame of the gene. Since the androgen-induced changes
in these histone marks at most sites were modest, we
next studied whether androgen induction also brings
about changes in histone density. Even though the total
amount of H3 in the absence of androgen was similar at
most sites in the locus, the occupancy of H3 around the
TSS was lower than in other parts of the gene.
Interestingly, androgen induction resulted in a decrease
in the H3 occupancy at many sites in the locus, with the
greatest drop around regions 5 and 6 (Figure 4C). Similar
changes were seen in H2B levels, strongly suggesting that
the changes in the H3 mirror nucleosome density in
general (data not shown).
Androgen-induced recruitment of BRM-containing
chromatin-remodeling complexes onto FKBP51 locus
The above changes in the histone density suggest that
chromatin remodeling complexes may be involved in the
androgen activation of the FKBP51 locus. Since SWI/
SNF complexes containing BRM or BRG1 as the major
ATPase subunit can catalyze nucleosome sliding and his-
tone transfer (12,13), we investigated whether androgen
induction is linked to any changes in the occupancy of
BRM- or BRG1-containing SWI/SNF complexes in the
locus. ChIP assays with antibodies against BRM showed
that androgen treatment of VCaP cells brings about very
robust recruitment of BRM onto regions 5 and 6, whereas
the occupancy of BRG1 in the locus remained very low
after the androgen exposure (Figure 5). Interestingly, the
regions around  10kb from the TSS occupying most
BRM were the same ones showing the most prominent
the AREs, and Arabic numerals indicate the regions ampliﬁed for enhancer analyzes and ChIP assays. (B) Sequences of the potential AREs in
FKBP51 gene. (Top) Position weight matrix used for identiﬁcation of putative AREs. The frequency of nucleotides at each of the 15 positions in
the ARE in the matrix is shown. (Lower) List of the in silico-identiﬁed AREs, their localization in the FKBP51 gene, sequences and type of ARE.
(C) Electrophoretic mobility shift assays were performed in the presence of AR-containing COS-1 cell extracts (AR+) or extracts from empty
vector-transfected cells (AR-), and
32P-labeled dsAREs or mutated (m) versions of AREIX and AREXIII. Protein–DNA complexes were resolved on
non-denaturing 4% polyacrylamide gels. The intronic ARE of prostatein peptide C3(1) was used as a positive control. (C, D) Transcriptional activity
of the ARE-containing 300-bp FKBP51 fragments was assessed by reporter gene assays. VCaP (D), COS-1 (E), LNCaP (F and G) cells were
transfected with TATA-LUC constructs driven by indicated regions of FKBP51 as described in Materials and Methods. For COS-1 (E) and
LNCaP+AR (G) analyses, pSG5-hAR (0.02 or 0.2mg/well, respectively) was cotransfected with the reporter constructs. Cotransfection of
pCMVb and b-galactosidase activity was used for normalization of transfection eﬃciency. The cells were treated with vehicle (EtOH) or 1nM
R1881 for 16h before harvesting the cells for reporter analyses. Results are shown as relative LUC activity and fold inductions of androgen-treated
samples in the relation to the activity of ethanol-treated samples are shown above the columns. Columns represent the mean SD of three inde-
pendent experiments.
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These results suggest that AR inﬂuences to the
chromatin structure of FKBP51 via recruitment of
BRM-containing complexes to the locus.
Effect of antiandrogen on FKBP51 transcription
and AR loading
Since increased AR protein levels have been reported to
convert antiandrogens, such as bicalutamide, to agonists
(35), it was of interest to investigate whether the diﬀerence
in the amount of AR between VCaP and LNCaP cells is
manifested in a diﬀerential response to the pure antagonist
bicalutamide (BIC). However, BIC alone displayed no or
minimal agonistic activity on FKBP51 mRNA accumula-
tion in LNCaP and VCaP cells (Figure 6A). BIC was
also capable of inhibiting R1881-induced accumulation
of FKBP51 mRNA in both cell lines, albeit the pure
antagonist was somewhat more potent in LNCaP cells
than in VCaP cells ( 90% versus  80% inhibition). As
in the case of pure agonists, the pure antagonist down-
regulated the AR protein in VCaP cells but not in LNCaP
Figure 3. Spatial and temporal loading of AR onto the FKBP51 locus in response to androgen exposure in VCaP cells. (A) Cells were treated with
1nM R1881 for indicated times and chromatin immunoprecipitations with anti-AR antibody followed by real-time PCR were carried out as
described in Materials and Methods section to investigate the occupancy of AR within 14 diﬀerent regions of FKBP51 gene. Enhancer and promoter
regions of PSA and distal enhancer region of TMPRSS2 served as known positive references, and a region in the middle of DSCAM was as a
negative control. ChIP assays with normal IgG monitored nonspeciﬁc binding. (B) Unsynchronized VCaP cells were treated with R1881 for indicated
times and ChIP samples were analyzed by ChIP with anti-AR or nonspeciﬁc IgG. The precipitated DNAs were used as templates for qPCR. Results
are shown as percentages of the input samples. Columns represent the mean SD of three experiments.
4142 Nucleic Acids Research, 2009, Vol. 37,No. 12Figure 4. Occupancy of RNA Polymerase II and occurrence of H3 modiﬁcations within the FKBP51 locus in VCaP cells. The cells were treated
with R1881 or vehicle (EtOH) for 2h and ChIP assays were performed using antibodies against AR (A), PolII (B), H3 (C), AcH3 (H3K9, K14ac)
(D), H3K4me3 (E) or H3K36me3 (F). ChIP samples were used as templates in quantitative PCR. Results are shown as fold over the normal rabbit
IgG-precipitated samples and represent the mean SD of three experiments.
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the FKBP51 chromatin in response to R1881 and BIC in
LNCaP and VCaP cells by ChIP and qPCR analysis. As
shown in Figure 6B, the overall pattern of agonist-induced
loading of AR to the locus was very similar in both cell
lines, but the level of AR occupancy was lower in LNCaP
cells than in VCaP cells. The latter ﬁnding very likely
reﬂects the diﬀerence in the amount of AR between the
cell lines. Interestingly, BIC alone was capable of promo-
ting binding of AR to the FKBP51 locus in VCaP cells but
not in LNCaP cells (Figure 6C). However, in agreement
with the minimal mRNA induction of FKBP51 upon BIC
exposure in VCaP cells, the BIC treatment did not bring
about signiﬁcant changes in the occupancy of PolII in the
locus (Supplementary Figure S4).
DISCUSSION
Knowledge of the molecular mechanisms of AR-
dependent transcription is essential for better understand-
ing of its role in prostate cancer development. On chro-
matin and target locus level, however, detailed analyses of
AR-targeted loci have been thus far limited to the PSA
gene (16–20). Moreover, only one model cell line, LNCaP,
has been employed in most of these studies. Here, we have
gathered molecular insight into the AR action by investi-
gating the regulation of FKBP51 transcription using
VCaP and LNCaP cells as model systems. The VCaP
cells are derived from a bone metastasis and express
ampliﬁed levels of wild-type AR, thus perhaps better
resembling the situation in hormone-refractory prostate
cancer than the LNCaP cells that correspond to a lymph
node metastasis with a ligand-binding domain T877A-
mutated version of the receptor (23). The rationale for
choosing the FKBP51 as a model gene is based on the
recent ﬁnding that the FKBP51 expression is more sensi-
tive to depletion of intraprostatic androgens than any
other AR target gene (22). Response of FKBP51 mRNA
to androgens has previously been observed also in LNCaP
cell and CWR22-R xenograft models (36–38). FKBP51
expression is also upregulated by glucocorticoids and
progestins in lymphocytes and breast cancer cells, respec-
tively (39,40). However, the molecular mechanisms of the
activation of FKBP51 chromatin by AR or glucocorticoid
receptor (GR) have not been addressed in detail.
FKBP51 (FKBP5) encodes a 51kDa FK506-binding
protein that belongs to the immunophilin protein family
(41). The exact role of FKBP51 is not known, but it
appears to play a role in protein folding and traﬃcking
(41). FKBP51 was discovered as a human homolog for
avian FKBP54 (42) that in turn was originally found in
progesterone receptor (PR) complexes (43). AR can inter-
act with FKBP51 and an increase in the immunophilin
level may augment the activity of AR (37). Interestingly,
FKBP51 protein levels are elevated in prostate cancer,
which may sensitize AR signaling (37,38). Also our statis-
tical analysis of the microarray data retrieved from the
Oncomine website (www.oncomine.org) indicates signiﬁ-
cantly increased expression of FKBP51 in prostate cancer
Figure 5. Androgen-induced recruitment of BRM-containing complexes onto the FKBP51 locus. VCaP cells were treated with R1881 or vehicle as in
Figure 4 and ChIP assays were performed using antibodies against BRM (A) or BRG1 (B) followed by quantitative PCR analysis. Results are shown
as fold over the normal rabbit IgG-precipitated samples and represent the mean SD of three experiments.
4144 Nucleic Acids Research, 2009, Vol. 37,No. 12in comparison to non-malignant prostate (Supplementary
Figure S5).
The reason for the fast and robust induction of FKBP51
by AR, in comparison to PSA, appears to be twofold.
Firstly, the FKBP51 is regulated purely at the level of
transcription, whereas a regulatory component requiring
new protein synthesis is involved in the activation of PSA
in VCaP cells and LNCaP cells (26). Secondly, several
AR-binding sites appear to synergize in the activation of
the FKBP51. Our in vitro testing of the potential AREs
together with quantitative ChIP scans revealed the pres-
ence of at least seven functional AREs within four distinct
enhancer regions located in the introns of the gene.
Interestingly, the two major enhancer regions harboring
multiple AREs are located very distal from the TSS, at
 87kb in the 5th intron (two AREs) and  98kb in the
7th intron (three AREs), with the farthermost acting as
the most active AR-regulated enhancer region of FKBP51
in isolation. Even though the single ARE-containing
regions at  25kb (1st intron) and  77kb (5th intron)
possessed in isolation only weak enhancer activity,
they showed signiﬁcant androgen-induced loading of AR
both in VCaP and LNCaP cells and are thus likely to
cooperate with the compound AREs in vivo.
Figure 6. Eﬀect of androgen and antiandrogen on FKBP51 transcription and AR loading in VCaP and LNCaP cells. (A) Accumulation of FKBP51
mRNA in response to exposure of VCaP and LNCaP cell to R1881 (1nM) or bicalutamide (BIC, 10mM) alone or their combination for 12h.
Messenger RNAs were analyzed by qRT-PCR analysis as described in Figure 1. (B) Immunoblotting analysis of AR protein levels in VCaP and
LNCaP cells in the presence and absence of BIC for 2 or 12h as indicated. (C) Loading of AR onto the FKBP51 locus in response to androgen or
antiandrogen exposure for 2h in VCaP cells and LNCaP cells. Cells were treated with vehicle, R1881 or BIC (10mM) as in Figure 4 and ChIP assays
were performed using antibody against AR followed by quantitative PCR analysis. Results are shown as percentages of the input samples and
represent the mean SD of three experiments.
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intron of FKBP51 are conserved in the corresponding
intron of mouse gene (at  65kb from TSS), and the
region was recently shown to occupy AR in mouse pros-
tate but not GR in mouse thymus (44). The lack of GR
occupancy in the 5th intron of Fkbp51 in the GR’s target
tissue thymus in vivo is somewhat unexpected, since both
the GR and the AR (and progesterone receptor, PR) rec-
ognize in vitro with a similar aﬃnity the non-selective
regulatory elements that are composed of 3-nt-spaced
inverted repeats of a 50-TGTTCT-30-type half-site
(29,45). The AREs in the 5th intron as most of the other
elements of the FKBP51 correspond to the latter, non-
selective- type response elements, which is in keeping
with the regulation of FKBP51 by several steroid hor-
mones. Two of the three AREs in the 7th intron
of human FKBP51 that were found and validated in
this study are conserved in the corresponding intron of
the mouse gene, but their function as AREs or GREs
has not been addressed in the previous studies. In contrast
to the role of distal elements, ChIP assays have recently
revealed that the regulation of Fkbp51 by progestins
occurs in breast cancer cells via an intronic enhancer
that resides relatively close ( 1.2kb) to the TSS (46).
In transfection-based reporter gene assays however, the
5th intronic region of the human gene has been reported
to confer progesterone response in breast cancer cells (39).
These results thus emphasize the importance of validation
of the putative steroid response elements under chromatin
environment by ChIP assays. Thus, even though AR, GR
and PR all recognize similar DNA elements in vitro and
often regulate same genes, such as FKBP51, these steroid
receptors seem to employ alternative binding sites in
chromatin to activate transcription in vivo. Since the
above analyses were carried out in diﬀerent cell types, it
is likely that diﬀerences in chromatin milieu signiﬁcantly
contributed to the observed diﬀerences in vivo. The role of
other ‘pioneering’ transcription factors binding close to
steroid receptor-occupied sites may also be important
(20,47), as GATA2 was shown to cooperate with the PR
in the regulation of Fkbp51 (46). However, according
to our unpublished data, GATA2 or FoxA1 do not play
a major role in the androgen regulation of FKBP51 in
VCaP cells (Makkonen,H., unpublished results).
Scanning of the chromatin structure of FKBP51 in
VCaP cells by ChIP showed a considerable enrichment
of acetylated H3 as well as trimethylated H3K4 nearby
the TSS, and K36 trimethylated H3 was prevalent
throughout the whole coding region of the gene. These
marks along their locations are typical to genes in active
chromatin (6,10). However, the above H3 modiﬁcations
were only modestly inﬂuenced by androgens, suggesting
that the FKBP51 locus existed in an active conformation
already prior to AR binding and the receptor was target-
ing pre-opened chromatin in prostate cancer cells. Similar
results have been reported for the PSA locus in LNCaP
cells (16). In keeping with the key role of AR in the acti-
vation and elongation of FKBP51 transcription, androgen
Figure 7. A spatial model of loop formation in the long-range regulation of the FKBP51 transcription by the AR transcription complex. ARs are
ﬁrst primarily loaded onto two very distal regions at  98 and  87kb downstream from the TSS. These two compound-ARE-containing enhancers
interact via coregulatory proteins, including BRM-containing SWI/SNF complexes, and cooperate with AR-occupying single-ARE regions at  78
and  25kb, which brings about further decrease in nucleosome density and recruitment of PolII tracking through the locus.
4146 Nucleic Acids Research, 2009, Vol. 37,No. 12induction brought about a clear increase in the occupancy
of PolII throughout the gene, whereas antiandrogen bica-
lutamide-bound receptor failed to do so, even though it
was in VCaP cells capable of promoting AR binding to the
locus. Androgen induction also resulted in a decrease in
histone density within the locus, which is likely to be
at least in part caused by recruitment of BRM-containing
chromatin remodeling complexes. The temporal and spa-
tial correlation between AR loading and recruitment of
BRM is in agreement with the previous reports that
AR predominantly employs a subfamily of SWI/SNF
complexes that depend on the BRM, but not on the
BRG1, ATPase (48,49).
The very distal enhancer elements are thought to com-
municate with the general transcription machinery at the
TSS thought chromatin looping. However, the challenges
associated with testing the existence of such loops and
the coordination of interactions of several AREs spanning
 100kb in FKBP51 are daunting. In our schematic model
(Figure 7), we propose that intricate cooperation between
multiple AREs orchestrate recruitment of coregulatory
complexes and PolII to the FKBP51 locus, which leads
to enhanced transcriptional rate of the PolII. Mediator
proteins, such as TRAP220, may potentially bridge AR
to PolII (50,51). However, our ChIP assays with anti-
TRAP220 antibody do not support a prominent role for
the mediator subunit as a bridging factor, which may not
be surprising, since there appears to be a lot of functional
redundancy among the AR coregulators (19).
Classic models of steroid receptor action view steroid
receptor-binding sites as regulatory elements in gene
promoters or their proximity as upstream enhancer ele-
ments. However, recent wider screens for their binding
sites imply that steroid-regulated promoters in most
cases lack proximal response elements. For example,
genome-wide screening of estrogen receptor binding sites
by ChIP combined with tiled microarray analysis indi-
cated that only a minority of estrogen receptor-binding
sites localize within 1kb promoter-proximal regions (52).
The same appears to hold true for AR-regulated genes, as
most of the AR-binding sites in chromosomes 21 and 22 as
well as among a selected sample of target genes seem to
reside >10kb from TSSs, often downstream of them
(20,53). Our current validated binding and functional
data of the FKBP51 locus also highlight the emerging bio-
logical importance of very long-range regulation via distal
enhancers by AR.
The nuclear organization of genome, i.e. how transcrip-
tion factors, their cognate binding sites and chromatin-
modifying complexes are organized with respect to each
other within the nucleus, is critical for the proper function
of our genome (54). Notably prostate cancers show strik-
ing genomic aberrations (55). The capability of AR to
regulate promoters from a long distance in chromatin
should thus be considered when evaluating the role of
AR in targeting novel genes and gene programs, especially
in malignant cells. Moreover, the issue concerning the
insulating mechanisms that should prevent distally
bound steroid receptors from promiscuously activating
other than their genuine target genes warrants emphasis
in further studies.
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